SARS-CoV-2 Serology and Virology Trends in Donors and Recipients of Convalescent Plasma

Dulipsingh, Latha; Ibrahim, Danyal; Schaefer, Ernst J.; Crowell, Rebecca; Diffenderfer, Margaret R.; Williams, Kendra N.; Lima, Colleen; McKenzie, Jessica M; Cook, Lisa D.; Puff, Jennifer; Onoroski, Mary; Wakefield, Dorothy; Eadie, Reginald; Kleiboeker, Steven B.; Nabors, Patricia; Hussain, Syed A.

doi:10.2139/ssrn.3669324

Cited by 11 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…35 Antiviral effects of CCP may occur through neutralizing antibodies, and it was reported that IgG and IgM anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were the primary isotype antibodies identified from COVID-19 patients treated with CCP. 36 This humoral immune response may inhibit protein S of SARS-CoV-2. 37 Thereafter, they may exert the protective effects against COVID-19.…”

Section: Discussionmentioning

confidence: 99%

Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis

et al. 2021

View full text Add to dashboard Cite

Background: Convalescent plasma (CCP) has been used for treating some infectious diseases; however, the efficacy of CCP in coronavirus disease 2019 (COVID-19) remains controversial. The aim of this research was to assess the efficacy of CCP as an adjunctive treatment in COVID-19 patients. Methods: Embase, PubMed, Web of Science, Cochrane and MedRix were searched for potentially relevant articles. All included papers were assessed for the quality using modified Jadad scale and Newcastle-Ottawa scale for randomized controlled trial (RCT) and non – RCT, respectively. We used a Q test and Egger test to assess the heterogeneity and publication bias among studies, respectively. Mortality rates between patients treated with standard treatment and standard treatment with CCP were compared using a Z test. Results: A total of 12 papers consisting of three cross-sectional studies, one prospective study, five retrospective studies, and three RCT studies were included in our analysis. Of them, a total of 1,937 patients treated with CCP and 3,405 patients without CCP were included. The risk of mortality was 1.92-fold higher in patients without CCP compared to patients treated with CCP (OR: 1.92; 95%CI: 1.33, 2.77; p=0.0005). In severe COVID-19 sub-group analysis, we found that patients without CCP had a 1.32 times higher risk of mortality than those treated with CCP (OR: 1.32; 95%CI: 1.09, 1.60; p=0.0040). Conclusions: CCP, as adjunctive therapy, could reduce the mortality rate among COVID-19 patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Upon identification of 753 univocal records, we selected 40 pertinent manuscripts. During the screening phase of these manuscripts, 15 were excluded: three studies did not report mortality data or compared mortality rate with national registries (Bradfute et al, 2020;Dulipsingh et al, 2020;Perotti et al, 2020); for two studies, we were unable to assess our inclusion criteria (Anakli et al, 2021;Skrip et al, 2020); seven had no comparative group (Dulipsingh et al, 2020;Gonzá lez et al, 2020;Jaiswal et al, 2021;Madariaga et al, 2020;Olivares-Gazca et al, 2020;Tremblay et al, 2020;Valentini et al, 2020); and three studies made use of plasma from non-convalescent, generic donors (De-Simone et al, 2021;Faqihi et al, 2020;Kamran et al, 2021). Of the 25 studies included for the quantitative meta-analysis, 10 were RCTs (Agarwal et al, 2020;AlQahtani et al, 2020;Avendano-Sola et al, 2020;Balcells et al, 2021;Gharbharan et al, 2020;Horby et al, 2021;Li et al, 2020a;Libster et al, 2021;Rasheed et al, 2020;Simonovich et al, 2020), while the other 15 were non-randomized studies with different designs (Abolghasemi et al, 2020;Alsharidah et al, 2021;Altuntas et al, 2021;Budhiraja et al, 2021;Donato et al, 2021;Duan et al, 2020;Hegerova et al, 2020;Joyner et al, 2021;Liu et al, 2020;Omrani et al, 2021;Salazar et al, 2020a;…”

Section: Resultsmentioning

confidence: 99%

Effect of time and titer in convalescent plasma therapy for COVID-19

Candia¹,

Prattichizzo²,

Garavelli³

et al. 2021

iScience

View full text Add to dashboard Cite

show abstract

“…35 Antiviral effects of CCP may occur through neutralizing antibodies, and it was reported that IgG of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and IgM SARS-CoV-2 were the primary isotype antibodies identified from COVID-19 patients treated with CCP. 36 This humoral immune response may inhibit protein S of SARS-CoV-2. 37 Thereafter, they may exert the protective effects against COVID-19.…”

Section: Discussionmentioning

confidence: 99%

Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis

et al. 2021

View full text Add to dashboard Cite

Background: Convalescent plasma (CCP) has been used for treating some infectious diseases; however, the efficacy of CCP in coronavirus disease 2019 (COVID-19) remains controversial. The aim of this research was to assess the efficacy of CCP as an adjunctive treatment in COVID-19 patients. Methods: Embase, PubMed, Web of Science, Cochrane and MedRix were searched for potentially relevant articles. All included papers were assessed for the quality using modified jadad scale and Newcaste-ottawa scale for randomized controlled trial (RCT) and non – RCT, respectively. We used a Q test and Egger test to assess the heterogeneity and publication bias among studies, respectively. Mortality rates between patients treated with standard treatment and standard treatment with CCP were compared using a Z test. Results: A total of 12 papers consisting of three cross-sectional studies, one prospective study, five retrospective studies, and two RCT studies were included in our analysis. Of them, a total of 1,937 patients treated with CCP and 3,405 patients without CCP were involved.. The risk of mortality was 1.92-fold higher in patients without CCP compared to patients treated with CCP (OR: 1.92; 95%CI: 1.33, 2.77; p=0.0005). In severe COVID-19 sub-group analysis, we found that patients without the CCP had a 1.32 times higher risk of mortality than those treated with the CCP (OR: 1.32; 95%CI: 1.09, 1.60; p=0.0040). Conclusions: CCP, as adjunctive therapy, reduces the mortality rate among COVID-19 patients.

show abstract

SARS-CoV-2 Serology and Virology Trends in Donors and Recipients of Convalescent Plasma

Cited by 11 publications

References 0 publications

Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis

Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis

Effect of time and titer in convalescent plasma therapy for COVID-19

Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis

Contact Info

Product

Resources

About